OPPM
IOVA icon

Opus Point Partners Management’s Iovance Biotherapeutics IOVA Stock Holding History

Opus Point Partners Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-29,934
Closed -$220K – 66
2017
Q2 		$220K Sell
29,934
-23,223
-44% -$148K 0.2% 61
2017
Q1 		$396K Buy
53,157
+14,210
+36% +$104K 0.29% 51
2016
Q4 		$271K Buy
38,947
+15,353
+65% +$106K 0.22% 43
2016
Q3 		$194K Sell
23,594
-632
-3% -$5.35K 0.11% 47
2016
Q2 		$196K Buy
+24,226
New +$152K 0.19% 41

Other funds holding IOVA

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Opus Point Partners Management's IOVA Position: Q3 2017 in Review

Opus Point Partners Management sold out of Iovance Biotherapeutics (IOVA) in Q3 2017, closing a stake of 29,934 shares — an estimated $220K sold.

Opus Point Partners Management first reported a position in IOVA in Q2 2016 and held it in 5 quarters. The position peaked at $396K in Q1 2017. 85 funds tracked by Wall St. Rank hold IOVA as of Q3 2017.

  • Opus Point Partners Management reported no remaining Iovance Biotherapeutics position as of Q3 2017 after selling out during the quarter.
  • Opus Point Partners Management sold 29,934 Iovance Biotherapeutics shares in Q3 2017, an estimated $220K.
  • Opus Point Partners Management first reported a position in Iovance Biotherapeutics in Q2 2016 and held it in 5 quarters.
  • Opus Point Partners Management's Iovance Biotherapeutics position peaked at $396K in Q1 2017.
  • 85 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2017.

Based on Opus Point Partners Management's 13F filing for Q3 2017, filed 14 Nov 2017.